KR20220118019A - Microneedle patch system for transdermal drug delivery - Google Patents
Microneedle patch system for transdermal drug delivery Download PDFInfo
- Publication number
- KR20220118019A KR20220118019A KR1020210021611A KR20210021611A KR20220118019A KR 20220118019 A KR20220118019 A KR 20220118019A KR 1020210021611 A KR1020210021611 A KR 1020210021611A KR 20210021611 A KR20210021611 A KR 20210021611A KR 20220118019 A KR20220118019 A KR 20220118019A
- Authority
- KR
- South Korea
- Prior art keywords
- drug
- microneedle patch
- microneedle
- skin
- support layer
- Prior art date
Links
- 238000013271 transdermal drug delivery Methods 0.000 title description 3
- 229940079593 drug Drugs 0.000 claims abstract description 121
- 239000003814 drug Substances 0.000 claims abstract description 121
- 239000010410 layer Substances 0.000 claims description 52
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 45
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 36
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 36
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 33
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 27
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 27
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 27
- 229920002674 hyaluronan Polymers 0.000 claims description 25
- 229960003160 hyaluronic acid Drugs 0.000 claims description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 12
- 238000001879 gelation Methods 0.000 claims description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 6
- 239000012790 adhesive layer Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002498 Beta-glucan Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 239000011241 protective layer Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 239000002250 absorbent Substances 0.000 abstract description 4
- 230000002745 absorbent Effects 0.000 abstract description 4
- 229940127022 high-dose drug Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 42
- 229920000642 polymer Polymers 0.000 description 25
- 229960003530 donepezil Drugs 0.000 description 21
- 235000000346 sugar Nutrition 0.000 description 17
- 229960003135 donepezil hydrochloride Drugs 0.000 description 16
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- -1 polyetherester Polymers 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000001856 Ethyl cellulose Substances 0.000 description 6
- 235000019325 ethyl cellulose Nutrition 0.000 description 6
- 229920001249 ethyl cellulose Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- FBPFZTCFMRRESA-NQAPHZHOSA-N Sorbitol Chemical compound OCC(O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-NQAPHZHOSA-N 0.000 description 5
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 5
- 229960000590 celecoxib Drugs 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010049264 Teriparatide Proteins 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 3
- 229960005460 teriparatide Drugs 0.000 description 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 3
- 229960001360 zolmitriptan Drugs 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 229960000759 risedronic acid Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
본 발명은 피부로 고용량의 약물을 지속적으로 투여하기 위한 마이크로니들 패치 시스템에 관한 것이다.The present invention relates to a microneedle patch system for continuously administering a high dose of a drug to the skin.
종래에 개발되어온 마이크로니들 약물전달시스템은, 마이크로니들에 약물을 코팅하거나, 마이크로니들을 약물을 포함한 용해형 마이크로니들로 제작하는 것이었다(특허문헌 1, 특개 2016-189844). 두 가지 시스템의 단점은 코팅될 수 있는 약물의 양이나 용해형 마이크로니들에 포함될 수 있는 약물의 양이 매우 제한적이어서 1 mg 이상의 약물을 탑재하는 것이 어렵거나 거의 불가능하다는 것이다. 따라서 마이크로니들로 적용할 수 있는 약물의 종류도 매우 제한적이어서 주사제나 기존 경피흡수약물전달 시스템을 대체하는데 큰 어려움이 있다.The conventionally developed microneedle drug delivery system has been to coat the microneedle with a drug or to manufacture the microneedle with a dissolving microneedle containing a drug (
앞선 두 가지 전략 이외에 "poke and patch" 방법이 있는데 약물이 없는 마이크로니들을 먼저 피부에 적용해 미세한 기공을 생성시키고 여기에 약물이 포함된 액제, 크림 혹은 패치를 적용해 약물의 피부투과도를 높이는 방법이다. 이 방법의 주요 단점은 미세 기공이 제한된 시간 동안만 열려 있어 활성 물질의 전달이 조기에 중단된다는 것이다. 일반적으로 마이크로니들 처리 부위는 3 내지 4시간 이내에 피부의 장벽 기능을 회복하고, 마이크로 채널은 천공 후 15 시간 내에 닫히는 것으로 알려져 있다. 하지만, 미세 기공이 발생한 피부를 폐쇄시키면(occlusion) 미세 기공이 72시간 동안 열린 상태가 유지된다는 보고가 있다(비특허문헌 1, Formation and Closure of Microchannels in Skin Following Microporation, Pharm Res (2011) 28:82-94, doi: 10.1007/s11095-010-0122-x). 이를 약물경피전달에 응용하기 위해서는 마이크로니들을 피부에 적용 후 제거하고 다시 약물이 포함된 제형을 피부에 적용한 후 피부를 폐쇄시켜야 하는 복잡한 절차를 거쳐야 하며, 이러한 연속적인 과정을 재현성 있게 환자들이 일반적으로 적용하는 것은 절차상 매우 불편하고 현실적으로 어렵다.In addition to the previous two strategies, there is a "poke and patch" method. First, a drug-free microneedle is applied to the skin to create micropores, and a liquid, cream or patch containing the drug is applied to increase the skin permeability of the drug. to be. The main disadvantage of this method is that the micropores are only open for a limited time, which leads to premature interruption of the delivery of the active substance. In general, it is known that the microneedle treatment site restores the skin barrier function within 3 to 4 hours, and the microchannel closes within 15 hours after puncture. However, there is a report that when the skin with micropores is closed (occlusion), the micropores are kept open for 72 hours (
본 발명의 일 측면은, 이전에 보고된 마이크로니들 전략들이 극복해내지 못한 어려움을 개선하여, 마이크로니들을 통한 고용량의 약물 전달이 가능해진 마이크로니들 패치 시스템을 제공한다.One aspect of the present invention provides a microneedle patch system that enables high-dose drug delivery through microneedles by improving the difficulties that previously reported microneedle strategies cannot overcome.
본 발명의 일 측면에서의 목적은, The object of one aspect of the present invention is,
기존 마이크로니들과 다르게 단위면적(1 cm2)당 약물의 함량을 최대 100 mg까지 증량시킬 수 있어 기존 경피흡수제 대비 단위면적당 약물의 함량이 더 높고, 마이크로니들에 의해 발생한 미세 기공을 통해 단기간(24시간 이내) 뿐만 아니라 장기간(약 3일 이상) 동안 고용량 약물의 체내 전달이 가능한 마이크로니들 패치를 제공하는 것이다.Unlike the existing microneedles, the content of the drug per unit area (1 cm 2 ) can be increased up to 100 mg, so the content of the drug per unit area is higher than that of the existing transdermal absorbents. It is to provide a microneedle patch capable of delivering high-dose drugs into the body for a long period of time (about 3 days or more) as well as within hours.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명의 일 측면은,One aspect of the present invention is
약물을 포함하는 마이크로니들;microneedles containing drugs;
상기 마이크로니들을 일 면에서 지지하며 약물을 포함하는 약물지지층;a drug support layer supporting the microneedle on one side and containing a drug;
상기 마이크로니들이 지지된 약물지지층 면의 반대측 면에 접하여 구비되며, 약물을 포함하지 않는 지지체; 및a support that is provided in contact with the surface opposite to the surface of the drug support layer on which the microneedle is supported, and does not contain a drug; and
상기 약물지지층이 접하여 있는 지지체 면의 반대측 면에 접하여 구비되는 밀폐성(occlusive) 배면층 필름을 포함하는 마이크로니들 패치이되,A microneedle patch comprising an occlusive back layer film provided in contact with the surface opposite to the surface of the support to which the drug support layer is in contact,
상기 밀폐성 배면층 필름은, 접하고 있는 지지체 면을 덮으며, 피부에 직접 부착 가능하도록 연장 형성된 점착층을 더 포함하는 것을 특징으로 하는, 마이크로니들 패치를 제공한다.The hermetic backing layer film provides a microneedle patch, which further comprises an adhesive layer extending so as to be able to be directly attached to the skin and cover the surface of the support body in contact.
본 발명의 일 측면에서 제공하는 마이크로니들 패치는,Microneedle patch provided in one aspect of the present invention,
기존 마이크로니들과 다르게 단위면적(1 cm2)당 약물의 함량을 최대 100 mg까지 증량시킬 수 있어 기존 경피흡수제 대비 단위면적당 약물의 함량이 더 높고, 마이크로니들에 의해 발생한 미세 기공을 통해 단기간(24시간 이내) 뿐만 아니라 장기간(약 3일 이상) 동안 고용량 약물의 체내 전달이 가능한 효과가 있다.Unlike the existing microneedles, the content of the drug per unit area (1 cm 2 ) can be increased up to 100 mg, so the content of the drug per unit area is higher than that of the existing transdermal absorbents. Within hours) as well as for a long period of time (about 3 days or more), it has the effect of enabling the delivery of high-dose drugs into the body.
도 1은 본 발명의 일 측면에서 제공하는 마이크로니들 패치 시스템의 구성을 나타내는 도면이다.
도 2는 본 발명의 일 측면에서 제공하는 마이크로니들 패치 시스템의 제조과정을 나타내는 개략도이다.
도 3은 구체예 1에 따라 도네페질 염산염 100mg이 포함되도록 제조된 마이크로니들과 약물지지층의 모습이다.
도 4는 구체예 4에 따라 세레콕시브(celecoxib) 10mg이 포함되도록 제조된 마이크로니들의 모습이다.
도 5는 고분자 물질과 당류 등으로 제조된 필름을 피부에 부착한 모습(좌측)과, 일정 시간 경과 후 겔화된 필름의 모습(우측)을 나타낸다.
도 6은 랫트에게 경구로 도네페질 3 mg/kg을 투여하거나, 피하주사로 도네페질 1 mg/kg을 투여하거나, 또는 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질 43 mg/kg을 투여한 후, 약물혈중농도 양상을 비교한 결과를 나타내는 그래프이다.
도 7은 랫트에게 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질을 투여하되, 도네페질 농도를 43 mg/kg, 80 mg/kg, 125mg/kg으로 각각 다르게 조절하여 약물혈중농도 양상을 비교한 결과를 나타내는 그래프이다.
도 8은 랫트에게 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질을 투여하되, 도네페질 80 mg/kg을 투여한 후 1시간만에 제거한 경우와 3일간 적용한 경우 약물혈중농도 양상을 비교한 결과를 나타내는 그래프이다.1 is a diagram showing the configuration of a microneedle patch system provided in one aspect of the present invention.
Figure 2 is a schematic diagram showing the manufacturing process of the microneedle patch system provided in one aspect of the present invention.
3 is a view of the microneedle and the drug support layer prepared to contain 100 mg of donepezil hydrochloride according to Example 1.
4 is a view of a microneedle prepared to contain 10 mg of celecoxib according to Example 4.
5 shows a state in which a film made of a polymer material and sugars, etc. is attached to the skin (left), and a state of the gelled film after a certain period of time (right).
6 shows the administration of
7 is a comparison of drug blood concentration patterns by administering donepezil to the rat using the microneedle patch prepared in Example, but adjusting the donepezil concentration differently to 43 mg/kg, 80 mg/kg, and 125 mg/kg. This is a graph showing the results.
8 is a comparison of the drug plasma concentration pattern when donepezil was administered to the rat using the microneedle patch prepared in Example, but removed within 1 hour after administration of donepezil 80 mg/kg, and when applied for 3 days; is a graph representing
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
한편, 본 발명의 실시 형태는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 이하 설명하는 실시 형태로 한정되는 것은 아니다. 또한, 본 발명의 실시 형태는 당해 기술분야에서 평균적인 지식을 가진 자에게 본 발명을 더욱 완전하게 설명하기 위해서 제공되는 것이다.On the other hand, the embodiment of the present invention may be modified in various other forms, and the scope of the present invention is not limited to the embodiments described below. In addition, the embodiments of the present invention are provided in order to more completely explain the present invention to those of ordinary skill in the art.
나아가, 명세서 전체에서 어떤 구성요소를 "포함"한다는 것은 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있다는 것을 의미한다.Furthermore, "including" a certain element throughout the specification means that other elements may be further included, rather than excluding other elements, unless otherwise stated.
본 발명의 일 측면은,One aspect of the present invention is
약물을 포함하는 마이크로니들;microneedles containing drugs;
상기 마이크로니들을 일 면에서 지지하며 약물을 포함하는 약물지지층;a drug support layer supporting the microneedle on one side and containing a drug;
상기 마이크로니들이 지지된 약물지지층 면의 반대측 면에 접하여 구비되며, 약물을 포함하지 않는 지지체; 및a support that is provided in contact with the surface opposite to the surface of the drug support layer on which the microneedle is supported, and does not contain a drug; and
상기 약물지지층이 접하여 있는 지지체 면의 반대측 면에 접하여 구비되는 밀폐성(occlusive) 배면층 필름을 포함하는 마이크로니들 패치이되,A microneedle patch comprising an occlusive back layer film provided in contact with the surface opposite to the surface of the support to which the drug support layer is in contact,
상기 밀폐성 배면층 필름은, 접하고 있는 지지체 면을 덮으며, 피부에 직접 부착 가능하도록 연장 형성된 점착층을 더 포함하는 것을 특징으로 하는, 마이크로니들 패치를 제공한다.The hermetic backing layer film provides a microneedle patch, which further comprises an adhesive layer extending so as to be able to be directly attached to the skin and cover the surface of the support body in contact.
본 발명에서 제시하는 마이크로니들 패치 시스템을 피부에 적용하면, 약물을 포함한 마이크로니들이 피부에 미세 기공을 발생시키고 그 미세 기공을 통해 용해성 마이크로니들에 포함된 약물의 확산이 일어나면서 빠르게 체내로 약물이 전달된다. 아울러, 마이크로니들을 지지하고 있던 고용량의 약물이 포함된 약물지지층은 피부에서 증발하는 수분을 흡수해 겔화되면서 약물의 저장소를 형성하게 되고, 앞서 마이크로니들이 형성시킨 미세 기공을 통해 지속적으로 약물이 체내로 전달된다. 약물이 포함된 겔화 가능한 약물지지층의 두께가 얇거나 강도가 충분하지 못할 경우 패치 시스템의 기계적 강도를 보강해 주는 지지체가 필요하며 이는 마이크로니들이 균일하게 피부를 관통할 수 있도록 지지하는 역할을 한다. 마이크로니들 패치 시스템의 가장 바깥에 위치한 밀폐성 배면층 필름은 패치 시스템이 피부에 잘 고정될 수 있도록 기능함과 동시에, 피부에서 증발되는 수분의 손실을 막아 지지층의 겔화를 촉진시키고 외부의 미생물과 이물을 차단해 미세 기공의 미생물 감염과 오염을 막는 역할을 한다.When the microneedle patch system presented in the present invention is applied to the skin, the microneedle containing the drug generates micropores in the skin, and the drug contained in the soluble microneedle is spread through the micropores, and the drug is rapidly delivered into the body. do. In addition, the drug support layer containing the high-capacity drug supporting the microneedle absorbs the moisture evaporated from the skin and gels to form a drug reservoir, and the drug continuously enters the body through the micropores previously formed by the microneedle. is transmitted When the thickness of the gelable drug support layer containing the drug is thin or the strength is insufficient, a support that reinforces the mechanical strength of the patch system is required, which serves to support the microneedles to penetrate the skin uniformly. The airtight back layer film located at the outermost part of the microneedle patch system functions to fix the patch system well on the skin, and at the same time prevents the loss of moisture evaporated from the skin, promotes the gelation of the support layer, and removes external microorganisms and foreign substances. It blocks micropores and prevents microbial infection and contamination.
이하, 본 발명의 일 측면에서 제공하는 마이크로니들 패치를 구성하는 구성들을, 각 구성별로 상세히 설명한다.Hereinafter, the components constituting the microneedle patch provided in one aspect of the present invention will be described in detail for each component.
(마이크로니들) 상기 마이크로니들은 피부 내부로 침습적으로 침투해 용해됨에 따라 약물이 방출될 수 있다. 즉, 마이크로니들은 용해성인 것이 바람직하며, 이에 히알루론산(Hyaluronic acid), 폴리비닐피롤리돈(polyvinylpyrrolidone; PVP), 폴리비닐알코올(polyvinyl alcohol; PVA), 소디움 카르복시메틸 셀룰로오스(sodium carboxymethyl cellulose) 및 당류로 이루어지는 군으로부터 선택되는 1종 이상의 혼합물로 형성되는 것일 수 있다. 이때, 당류는 단당류, 이당류 및 다당류로 이루어지는 군으로부터 선택되는 1종 이상일 수 있으며, 더욱 구체적으로 단당류는 과당(Fructose), 갈락토스(Galactose), 글루코스(Glucose) 및 만노스(Mannose)로 이루어지는 군으로부터 선택되는 1종 이상이고; 상기 이당류는 수크로스(Sucrose), 락토스(Lactose), 말토스(maltose), 트레할로스(Trehalose), 투라노스(Turanose) 및 셀로비오스(Cellobiose)로 이루어지는 군으로부터 선택되는 1종 이상이고; 및 상기 다당류는 덱스트란(Dextran), 디에틸아미노에틸-덱스트란(Diethylamino ethyl-Dextran), 덱스트린(Dextrin), 셀룰로오스(Cellulose) 및 베타-글루칸(β-Glucans)으로 이루어지는 군으로부터 선택되는 1종 이상일 수 있다. 상기 마이크로니들은 원뿔 형상, 사각뿔 형상 및 삼각뿔 형상으로 이루어지는 군으로부터 선택되는 1종 이상의 형상일 수 있으나, 특별히 특정 형상으로 제한되는 것은 아니다.(Microneedle) The drug may be released as the microneedle invasively penetrates into the skin and dissolves. That is, it is preferable that the microneedle is soluble, and thus, hyaluronic acid, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), sodium carboxymethyl cellulose and It may be formed of a mixture of one or more selected from the group consisting of saccharides. In this case, the saccharide may be at least one selected from the group consisting of monosaccharides, disaccharides and polysaccharides, and more specifically, the monosaccharides are selected from the group consisting of fructose, galactose, glucose and mannose. at least one of which is; The disaccharide is at least one selected from the group consisting of sucrose, lactose, maltose, trehalose, turanose and cellobiose; And the polysaccharide is one selected from the group consisting of dextran, diethylamino ethyl-dextran, dextrin, cellulose, and beta-glucan (β-Glucans) may be more than The microneedle may have at least one shape selected from the group consisting of a cone shape, a quadrangular pyramid shape, and a triangular pyramid shape, but is not particularly limited to a specific shape.
(약물지지층) 상기 약물지지층은 피부로부터 방출되는 수분에 의해 겔화되며, 상기 약물지지층의 겔화로 인해, 약물지지층에 포함되어 있던 약물이 방출될 수 있다. 상기 약물지지층의 겔화로 인해 방출되는 약물은, 마이크로니들로 인해 형성된 피부의 미세 기공을 통해 체내로 흡수된다. 약물지지층은 히알루론산(Hyaluronic acid), 폴리비닐피롤리돈(polyvinylpyrrolidone; PVP), 폴리비닐알코올(polyvinyl alcohol; PVA), 소디움 카르복시메틸 셀룰로오스(sodium carboxymethyl cellulose, NaCMC), 폴록사머(poloxamer), 카보머(carbomer), 히프로멜로오스(hypromellose), 히드록시프로필셀룰로오스(Hydroxypropyl cellulose; HPC), 히드록시에틸셀룰로오스(Hydroxyethyl cellulose; HEC), 소디움 알지네이트(sodium alginate), 당류, 글리세린(glycerin), 프로필렌글리콜(propylene glycol), 폴리에틸렌글리콜 400(polyethylene glycol 400) 및 소르비톨(sorbitol; SB)로 이루어지는 군으로부터 선택되는 1종 이상의 혼합물로 형성된 것일 수 있으며, 상기 마이크로니들을 형성하는 물질과 종류가 동일할 수도, 상이할 수도 있다.(Drug support layer) The drug support layer is gelled by moisture released from the skin, and due to the gelation of the drug support layer, the drug contained in the drug support layer may be released. The drug released due to the gelation of the drug support layer is absorbed into the body through the micropores of the skin formed by the microneedles. The drug support layer is hyaluronic acid, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), sodium carboxymethyl cellulose (NaCMC), poloxamer, carbo Mer (carbomer), hypromellose (hypromellose), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (Hydroxyethyl cellulose; HEC), sodium alginate (sodium alginate), sugar, glycerin (glycerin), propylene It may be formed of one or more mixtures selected from the group consisting of glycol (propylene glycol), polyethylene glycol 400 (polyethylene glycol 400), and sorbitol (SB), and may be the same as the material forming the microneedle. , may be different.
(지지체) 상기 지지체는 약물지지층의 두께가 얇거나 강도가 충분하지 못할 경우 패치 시스템의 기계적 강도를 보강해 주는 역할을 하며, 이는 마이크로니들이 균일하게 피부를 관통할 수 있도록 지지하는 역할을 한다. 지지체는 생체적합성 물질로 고분자류, 세라믹류, 및 금속류 등을 사용해 제조할 수 있다. 생체 적합성 물질의 예로는, 히알루론산(hyaluronic acid), 알지닉산(alginic acid), 펙틴, 카라기난, 콘드로이틴(설페이트), 덱스트란(설페이트), 키토산, 폴리라이신(polylysine), 콜라겐, 젤라틴, 카르복시메틸 키틴(carboxymethyl chitin), 피브린, 아가로스, 풀루란 폴리락타이드, 폴리글리코라이드(PGA), 폴리락타이드-글리코라이드 공중합체(PLGA), 풀루란 폴리안하이드라이드(polyanhydride), 폴리오르쏘에스테르(polyorthoester), 폴리에테르에스테르(polyetherester), 폴리카프로락톤(polycaprolactone), 폴리에스테르아마이드(polyesteramide), 폴리(뷰티릭 산), 폴리(발레릭 산), 폴리우레탄, 폴리아크릴레이트, 에틸렌-비닐아세테이트 중합체, 아크릴 치환 셀룰로오스 아세테이트, 비-분해성 폴리우레탄, 폴리스티렌, 폴리비닐 클로라이드, 폴리비닐 풀루오라이드, 폴리(비닐 이미다졸), 클로로설포네이트 폴리올레핀(chlorosulphonate polyolefins), 폴리에틸렌 옥사이드, 폴리비닐피롤리돈(PVP), 폴리에틸렌글리콜(PEG), 폴리메타크릴레이트, 하이드록시프로필메틸셀룰로오스(HPMC), 에틸셀룰로오스(EC), 하이드록시프로필셀룰로오스(HPC), 카복시메틸셀루로스, 싸이클로덱스트린 및 이러한 고분자를 형성하는 단량체들의 공중합체와 셀룰로오스의 군에서 선택된 어느 하나 이상을 포함한 물질 등이 있다. 후술하는 실시예에서는 폴리비닐피롤리돈(PVP)을 사용하였다.(Support) The support serves to reinforce the mechanical strength of the patch system when the thickness of the drug support layer is thin or the strength is insufficient, which serves to support the microneedles to penetrate the skin uniformly. The support is a biocompatible material and can be prepared using polymers, ceramics, metals, and the like. Examples of biocompatible materials include hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl Chitin (carboxymethyl chitin), fibrin, agarose, pullulan polylactide, polyglycolide (PGA), polylactide-glycolide copolymer (PLGA), pullulan polyanhydride, polyorthoester (polyorthoester), polyetherester, polycaprolactone, polyesteramide, poly(butyric acid), poly(valeric acid), polyurethane, polyacrylate, ethylene-vinyl acetate Polymers, acrylic substituted cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone ( PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin and There is a material including at least one selected from the group of copolymers of monomers and cellulose. In Examples to be described later, polyvinylpyrrolidone (PVP) was used.
(밀폐성 배면층 필름) 상기 밀폐성 배면층 필름은 피부로부터 방출되는 수분에 대해 반투과성이거나 방습성일 수 있다. 즉, 상기 밀폐성 배면층 필름은 피부로부터 방출되는 수분의 손실을 막아, 상기 약물지지층의 겔화를 조절, 또는 촉진하는 것일 수 있다. 사람의 피부에서는 24시간당 240-1,920 g/m2의 속도로 수분이 증발되고 있고, 상처가 있을 경우 약 4,800 g/m2의 속도로 수분이 증발된다. 상기 밀폐성 배면층 필름은 피부로부터 증발되는 수분의 손실을 막음으로써, 마이크로니들 패치가 피부에 부착된 동안 마이크로니들로 인해 형성된 피부의 미세 기공이 개방된 상태로 유지될 수 있다. 종래 기술의 경우, 마이크로니들로 인해 형성된 피부의 미세 기공이 제한된 시간 동안만 열려 있어(일반적으로, 마이크로니들 처리 부위는 3 내지 4시간 이내에 피부의 장벽 특성을 회복하기 시작함) 활성 물질의 전달이 조기에 중단되는 문제가 있었으나, 미세 기공이 발생한 피부를 밀폐하였을 때 미세 기공이 장시간(72시간 이상) 유지되어, 지지층에 포함되어 있던 약물이 지속적으로 피부로 전달될 수 있는 것이다. 밀폐성 배면층 필름은 수증기, 산소 및 이산화탄소의 투과가 가능하고 방수가 되며 박테리아 침투가 불가능한 반투과성의 필름으로 주로 폴리우레탄류, 폴리에틸렌류, 나일론 유도체류 등의 필름에 아크릴 계열의 점착제가 도포되어 있어 피부 부착이 가능한 형태이다. 이러한 특징을 가진 필름으로 시판되고 있는 예로는 3M사의 테가덤 필름(Tegaderm™ Film), 스미스앤드네퓨(주)사의 옵사이트 플렉시그리드(Opsite™ Flexigrid), 옵사이트 플렉시픽스(OpSite™ Flexifix) 등이 있으나 이에 한정되는 것은 아니다. 밀폐성 배면층 필름의 또 다른 중요한 역할은 외부로부터 박테리아의 침입을 막아 마이크로니들로 인한 발생한 미세 기공이 세균으로부터 오염되는 것을 막는 것이다. 후술하는 실시예에서는 테가덤 필름(3M)을 사용하였다.(Healable Back Layer Film) The hermetic back layer film may be semi-permeable to moisture released from the skin or moisture-proof. That is, the hermetic back layer film may prevent the loss of moisture released from the skin, thereby controlling or facilitating the gelation of the drug support layer. In human skin, water evaporates at a rate of 240-1,920 g/m 2 per 24 hours, and when there is a wound, water evaporates at a rate of about 4,800 g/m 2 . The hermetic back layer film prevents the loss of moisture evaporated from the skin, so that the micropores of the skin formed by the microneedles can be maintained in an open state while the microneedle patch is attached to the skin. In the case of the prior art, the micropores of the skin formed by the microneedles are only open for a limited time (generally, the microneedle treatment site begins to restore the barrier properties of the skin within 3 to 4 hours), so that the delivery of the active substance is difficult. There was a problem of early stopping, but when the skin in which the micropores occurred was closed, the micropores were maintained for a long time (72 hours or more), so that the drug contained in the support layer can be continuously delivered to the skin. The hermetic back layer film is a semi-permeable film that can permeate water vapor, oxygen and carbon dioxide, is waterproof, and cannot penetrate bacteria. It is a form that can be attached. Examples of commercially available films with these characteristics include 3M's Tegaderm™ Film, Smith &Nephew's Opsite™ Flexigrid, and OpSite™ Flexifix. However, the present invention is not limited thereto. Another important role of the hermetic backing layer film is to prevent the intrusion of bacteria from the outside to prevent contamination of micropores caused by microneedles from bacteria. In Examples to be described later, a Tegaderm film (3M) was used.
본 발명의 일 측면에서 제공하는 마이크로니들 패치는, 피부에 사용하기 이전에, 점착층을 보호하는 보호층을 더 포함할 수 있다. 또한, 상기 마이크로니들 및/또는 지지층에 포함되는 약물은 화학 약물(저분자 약물)뿐만 아니라, 펩티드나 단백질 약물도 적용하여 경피흡수 제형으로 사용 가능하다.The microneedle patch provided in one aspect of the present invention may further include a protective layer for protecting the adhesive layer before use on the skin. In addition, the drug included in the microneedle and/or the support layer can be used as a transdermally absorbed formulation by applying not only chemical drugs (low molecular weight drugs) but also peptides or protein drugs.
본 발명의 일 측면에서 제공하는 마이크로니들 패치는, 기존 마이크로니들과 다르게 단위면적(1 cm2)당 약물의 함량을 최대 100 mg까지 증량시킬 수 있어 기존 경피흡수제 대비 단위면적당 약물의 함량이 더 높고, 마이크로니들에 의해 발생한 미세 기공을 통해 단기간(24시간 이내) 뿐만 아니라 장기간(약 3일 이상) 약물의 체내 전달이 가능한 효과가 있으며, 이는 후술하는 실시예, 실험예에 의해 뒷받침된다.The microneedle patch provided in one aspect of the present invention, unlike the existing microneedle, can increase the drug content per unit area (1 cm 2 ) up to 100 mg, so that the content of the drug per unit area is higher than that of the existing transdermal absorbents. , there is an effect that the drug can be delivered into the body for a short period (within 24 hours) as well as for a long period (about 3 days or more) through the micropores generated by the microneedles, which is supported by Examples and Experimental Examples to be described later.
이하, 본 발명을 제조예, 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Preparation Examples, Examples and Experimental Examples.
단, 하기의 제조예, 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용과 범위가 하기 내용으로 한정되는 것은 아니다.However, the following Preparation Examples, Examples, and Experimental Examples are merely illustrative of the present invention, and the content and scope of the present invention are not limited to the following.
<실시예> 마이크로니들 패치 제조<Example> Preparation of microneedle patch
하기 (1) 내지 (8) 과정을 통해 본 발명의 일 측면에서 제공하는 마이크로니들 패치 시스템을 제조하였으며, 본 실시예에 따른 마이크로니들 패치 시스템 제조방법을 나타내는 개략도를 도 2에 나타내었다.The microneedle patch system provided in one aspect of the present invention was manufactured through the following processes (1) to (8), and FIG. 2 is a schematic diagram showing a method for manufacturing the microneedle patch system according to this embodiment.
(1): 3D 프린터나 미세공정을 이용해 마이크로니들 원형(master)을 제작한다.(1): A microneedle master is produced using a 3D printer or microprocessing.
(2): 실리콘(polydimethylsiloxane; PDMS)으로 마이크로니들 몰드(female mold)를 제작한다.(2): A microneedle mold (female mold) is made of silicon (polydimethylsiloxane; PDMS).
(3): 마이크로니들부와 고용량 약물지지층에 사용할 고분자 용액을 제조하며, 이때 약물을 함께 포함시켜 고분자 용액을 제조한다.(3): Prepare a polymer solution to be used for the microneedle part and the high-capacity drug support layer. At this time, the polymer solution is prepared by including the drug.
(4): 마이크로니들부 형성을 위해, 상기 (3)에서 제조한 소량의 고분자 용액을, 상기 (2)에서 제조한 마이크로니들 몰드에 붓고 용매를 건조한다.(4): To form the microneedle part, a small amount of the polymer solution prepared in (3) is poured into the microneedle mold prepared in (2), and the solvent is dried.
(5): 고용량 약물지지층 형성을 위해, 상기 (3)에서 제조한 고분자 용액을, 상기 (4)의 마이크로니들 몰드에 붓고 용매를 건조한다.(5): To form a high-capacity drug support layer, the polymer solution prepared in (3) is poured into the microneedle mold of (4), and the solvent is dried.
(6): 상기 (5)의 약물지지층 위로 약물이 없는 생체적합성 지지체를 추가한다.(6): Add a drug-free biocompatible support on the drug support layer of (5) above.
(7): 니들부가 손상되지 않도록 디몰딩한다.(7): De-molding so as not to damage the needle part.
(8): 밀폐성(폐쇄성) 배면층 필름을 (6)에 형성된 지지체 외부에 부착한다.(8): A hermetic (closable) backing layer film is attached to the outside of the support formed in (6).
상기 (3)에서 제조한 고분자 용액은 하기 성분을 포함한다.The polymer solution prepared in (3) above includes the following components.
구체예 1: 약물로 도네페질(donepezil) 포함 (동물실험에 사용한 실시예) Specific Example 1 : Containing donepezil as a drug (Example used in animal experiments)
- 약물 (도네페질 염산염, Donepezil hydrochloride) 5%(w/w) - Drug (Donepezil hydrochloride, Donepezil hydrochloride) 5% (w/w)
- 고분자 (폴리비닐피롤리돈, PVP) 15%(w/w) - Polymer (polyvinylpyrrolidone, PVP) 15% (w/w)
- 당류 (트레할로오스, Trehalose) 5%(w/w) - Sugar (trehalose, Trehalose) 5% (w/w)
- 용매 (증류수, DW) 75%(w/w) - Solvent (distilled water, DW) 75% (w/w)
구체예 2: 약물로 도네페질(donepezil) 포함 Embodiment 2 : Including donepezil as a drug
- 약물 (도네페질 염산염, Donepezil hydrochloride) 8%(w/w) - Drugs (Donepezil hydrochloride, Donepezil hydrochloride) 8% (w/w)
- 고분자 (폴리비닐피롤리돈, PVP) 15%(w/w) - Polymer (polyvinylpyrrolidone, PVP) 15% (w/w)
- 당류 (트레할로오스, Trehalose) 5%(w/w) - Sugar (trehalose, Trehalose) 5% (w/w)
- 용매 (증류수, DW) 72%(w/w) - Solvent (distilled water, DW) 72% (w/w)
구체예 3: 약물로 도네페질(donepezil) 포함 Embodiment 3 : Including donepezil as a drug
- 약물 (도네페질 염산염, Donepezil hydrochloride) 2.5%(w/w) - Drug (Donepezil hydrochloride, Donepezil hydrochloride) 2.5% (w/w)
- 고분자 (히알루론산, HA) 1.0%(w/w) - Polymer (hyaluronic acid, HA) 1.0% (w/w)
- 당류 (트레할로오스, Trehalose) 1.5%(w/w) - Sugar (trehalose, Trehalose) 1.5% (w/w)
- 용매 (증류수, DW) 95%(w/w) - Solvent (distilled water, DW) 95% (w/w)
구체예 4: 약물로 세레콕시브(celecoxib) 포함 Embodiment 4 : Including celecoxib as a drug
- 약물 (세레콕시브, Celecoxib) 5%(w/w) - Drug (celecoxib, Celecoxib) 5% (w/w)
- 고분자 (폴리비닐피롤리돈, PVP) 15%(w/w) - Polymer (polyvinylpyrrolidone, PVP) 15% (w/w)
- PEG 400 5%(w/w) - PEG 400 5% (w/w)
- 용매 (에탄올, EtOH) 75%(w/w) - Solvent (ethanol, EtOH) 75% (w/w)
구체예 5: 약물로 인슐린(insulin) 포함 Embodiment 5 : Including insulin (insulin) as a drug
- 약물 (인슐린, Insulin) 2.0%(w/w)- Drug (insulin, Insulin) 2.0% (w/w)
- 고분자 (히알루론산, HA) 1.0%(w/w)- Polymer (hyaluronic acid, HA) 1.0% (w/w)
- 당류 (트레할로오스, Trehalose) 2.0%(w/w)- Sugar (trehalose, Trehalose) 2.0% (w/w)
- 용매 (증류수, DW) 95%(w/w)- Solvent (distilled water, DW) 95% (w/w)
구체예 6: 약물로 사람성장호르몬(human growth hormone) 포함 Embodiment 6 : Including human growth hormone as a drug
- 약물 (사람성장호르몬, hGH) 2.0%(w/w)- Drug (human growth hormone, hGH) 2.0% (w/w)
- 고분자 (히알루론산, HA) 1.5%(w/w)- Polymer (hyaluronic acid, HA) 1.5% (w/w)
- 당류 (트레할로오스, Trehalose) 1.5%(w/w)- Sugar (trehalose, Trehalose) 1.5% (w/w)
- 용매 (증류수, DW) 95%(w/w)- Solvent (distilled water, DW) 95% (w/w)
구체예 7: 약물로 테리파라타이드(teriparatide) 포함 Embodiment 7 : Including teriparatide as a drug
- 약물 (테리파라타이드, Teriparatide) 1.0%(w/w)- Drug (teriparatide, Teriparatide) 1.0% (w/w)
- 고분자 (히알루론산, HA) 1.0%(w/w)- Polymer (hyaluronic acid, HA) 1.0% (w/w)
- 당류 (트레할로오스, Trehalose) 1.5%(w/w)- Sugar (trehalose, Trehalose) 1.5% (w/w)
- 용매 (증류수, DW) 96.5%(w/w)- Solvent (distilled water, DW) 96.5% (w/w)
구체예 8: 약물로 졸미트립탄(zolmitriptan) 포함 Embodiment 8 : Including zolmitriptan as a drug
- 약물 (졸미트립탄, zolmitriptan) 1.0%(w/w)- Drug (zolmitriptan, zolmitriptan) 1.0% (w/w)
- 고분자 (히알루론산, HA) 1.0%(w/w)- Polymer (hyaluronic acid, HA) 1.0% (w/w)
- 당류 (말토스, maltose) 1.5%(w/w)- Sugar (maltose, maltose) 1.5% (w/w)
- 용매 (증류수, DW) 96.5%(w/w)- Solvent (distilled water, DW) 96.5% (w/w)
구체예 9: 약물로 리세드론산나트륨(risedronate sodium) 포함 Embodiment 9 : Including risedronate sodium as a drug
- 약물 (리세드론산나트, Risedronate sodium) 1.0%(w/w)- Drug (Risedronate sodium) 1.0% (w/w)
- 고분자 (히알루론산, HA) 1.0%(w/w)- Polymer (hyaluronic acid, HA) 1.0% (w/w)
- 당류 (트레할로오스, Trehalose) 2.0%(w/w)- Sugar (trehalose, Trehalose) 2.0% (w/w)
- 용매 (증류수, DW) 96%(w/w)- Solvent (distilled water, DW) 96% (w/w)
구체예 10: 약물로 도네페질(donepezil) 포함 Embodiment 10 : Including donepezil as a drug
- 약물 (도네페질 염산염, Donepezil hydrochloride) 2.5%(w/w)- Drug (Donepezil hydrochloride, Donepezil hydrochloride) 2.5% (w/w)
- 고분자 (소디움 카르복시메틸 셀룰로오스, NaCMC) 1.0%(w/w)- Polymer (sodium carboxymethyl cellulose, NaCMC) 1.0% (w/w)
- 당류 (소르비톨, SB) 1.5%(w/w)- Sugar (sorbitol, SB) 1.5% (w/w)
- 용매 (증류수, DW) 95%(w/w)- Solvent (distilled water, DW) 95% (w/w)
구체예 11: 약물로 도네페질(donepezil) 포함 Embodiment 11 : Including donepezil as a drug
- 약물 (도네페질 염산염, Donepezil hydrochloride) 2.5%(w/w)- Drug (Donepezil hydrochloride, Donepezil hydrochloride) 2.5% (w/w)
- 고분자 (폴리비닐알코올, PVA) 1.0%(w/w)- Polymer (polyvinyl alcohol, PVA) 1.0% (w/w)
- 당류 (트레할로오스, Trehalose) 1.5%(w/w)- Sugar (trehalose, Trehalose) 1.5% (w/w)
- 용매 (증류수, DW) 95%(w/w)- Solvent (distilled water, DW) 95% (w/w)
구체예 12: 약물로 도네페질(donepezil) 포함 Embodiment 12 : Including donepezil as a drug
■ 마이크로니들 고분자 용액■ Microneedle polymer solution
- 약물 (도네페질 염산염, Donepezil hydrochloride) 2.5%(w/w)- Drug (Donepezil hydrochloride, Donepezil hydrochloride) 2.5% (w/w)
- 고분자 (히알루론산, HA) 1.0%(w/w)- Polymer (hyaluronic acid, HA) 1.0% (w/w)
- 당류 (트레할로오스, Trehalose) 1.5%(w/w)- Sugar (trehalose, Trehalose) 1.5% (w/w)
- 용매 (증류수, DW) 95%(w/w)- Solvent (distilled water, DW) 95% (w/w)
■ 약물지지층 고분자 용액■ Drug support layer polymer solution
- 약물 (도네페질 염산염, Donepezil hydrochloride) 8%(w/w)- Drugs (Donepezil hydrochloride, Donepezil hydrochloride) 8% (w/w)
- 고분자 (폴리비닐피롤리돈, PVP) 15%(w/w)- Polymer (polyvinylpyrrolidone, PVP) 15% (w/w)
- 당류 (트레할로오스, Trehalose) 5%(w/w)- Sugar (trehalose, Trehalose) 5% (w/w)
- 용매 (증류수, DW) 72%(w/w)- Solvent (distilled water, DW) 72% (w/w)
도 3은 구체예 1에 따라 도네페질 염산염 100mg이 포함되도록 제조된 마이크로니들과 약물지지층의 모습이다.3 is a view of the microneedle and the drug support layer prepared to contain 100 mg of donepezil hydrochloride according to Example 1.
도 4는 구체예 4에 따라 세레콕시브(celecoxib) 10mg이 포함되도록 제조된 마이크로니들의 모습이다.4 is a view of a microneedle prepared to contain 10 mg of celecoxib according to Example 4.
<실험예 1> 피부에서 증발하는 수분을 흡수해 겔화되면서 약물의 저장소를 형성하는 고체 지지층의 겔화 특성 평가<Experimental Example 1> Evaluation of gelation properties of a solid support layer that absorbs moisture evaporated from the skin and forms a reservoir for the drug
본 발명의 일 측면에서 제공하는 약물 저장소의 겔화 특성을 평가하기 위하여 아래와 같은 실험을 수행하였다.In order to evaluate the gelation characteristics of the drug reservoir provided in one aspect of the present invention, the following experiment was performed.
아래의 고분자 물질과 당류 등의 혼합물을 용매에 용해시키거나 분산시킨 후 자동 도공장치 (KP-3000, 기배이앤티)를 이용하여 두께 0.5mm의 필름을 제조하고 가로와 세로의 크기가 1cm가 되도록 필름을 절단하였다. 절단된 필름을 팔뚝부위 피부에 올리고 그 위에 테가덤 필름을 부착해 1시간 후에 겔화가 되었는지 여부를 판단하였다. 도 5는 피부에 부착 직후 필름의 모습(좌)과 일정 시간 경과 후 겔화된 필름의 모습(우)을 나타낸다.After dissolving or dispersing the following mixture of polymer and sugar in a solvent, use an automatic coating device (KP-3000, Gibai E&T) to prepare a film with a thickness of 0.5 mm, The film was cut. The cut film was placed on the skin of the forearm, and a Tegaderm film was attached thereon to determine whether gelation occurred after 1 hour. 5 shows the appearance of the film immediately after attachment to the skin (left) and the appearance of the gelled film after a certain period of time (right).
고분자 물질 성분: Polymer Ingredients :
히알루론산 (hyaluronic acid; HA)hyaluronic acid (HA)
폴리비닐피롤리돈 (polyvinylpyrrolidone; PVP)polyvinylpyrrolidone (PVP)
폴리비닐알코올 (polyvinyl alcohol; PVA)polyvinyl alcohol (PVA)
소디움 카르복시메틸 셀룰로오스 (sodium carboxymethyl cellulose; NaCMC)Sodium carboxymethyl cellulose (NaCMC)
폴록사머 (poloxamer; PX)Poloxamer (PX)
카보머 (carbomer; CM)Carbomer (CM)
히프로멜로오스 (hypromellose; HPMC)hypromellose (HPMC)
히드록시프로필셀룰로오스 (hydroxypropyl cellulose; HPC)Hydroxypropyl cellulose (HPC)
히드록시에틸셀룰로오스 (hydroxyethyl cellulose; HEC)hydroxyethyl cellulose (HEC)
소디움 알지네이트 (sodium alginate; NaA)Sodium alginate (NaA)
에틸셀룰로오스 (ethyl cellulose, EC)ethyl cellulose (EC)
당류 등 성분: Ingredients such as sugars :
트레할로즈 (trehalose; TH)trehalose (TH)
글리세린 (glycerin; GL)glycerin (GL)
프로필렌글리콜 (propylene glycol; PG)Propylene glycol (PG)
폴리에틸렌글리콜 400 (polyethylene glycol 400; PEG)Polyethylene glycol 400 (polyethylene glycol 400; PEG)
소르비톨 (sorbitol; SB)Sorbitol (SB)
그 결과를 하기 표 1에 나타내었다.The results are shown in Table 1 below.
<실험예 2> 마이크로니들 패치의 약물방출 특성 평가<Experimental Example 2> Evaluation of drug release characteristics of microneedle patch
본 발명의 일 측면에서 제공하는 마이크로니들 패치의 약물방출 특성을 평가하기 위하여, 아래와 같은 실험을 수행하였다.In order to evaluate the drug release characteristics of the microneedle patch provided in one aspect of the present invention, the following experiment was performed.
보다 구체적으로, 랫트에게 경구로 도네페질 3 mg/kg을 투여하거나, 피하주사로 도네페질 1 mg/kg을 투여하거나, 또는 상기 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질 43 mg/kg을 투여한 후, 약물혈중농도 양상을 비교하였고, 그 결과를 도 6에 나타내었다.More specifically, 3 mg/kg of donepezil was orally administered to the rat, 1 mg/kg of donepezil was administered by subcutaneous injection, or 43 mg/kg of donepezil was administered using the microneedle patch prepared in the above Example. After administration, the drug plasma concentration pattern was compared, and the results are shown in FIG. 6 .
도 6에 나타난 바와 같이, 경구투여와 피하주사 처리군(대조군)의 경우 약 1일만에 약물혈중농도가 매우 낮아지는 것으로 확인되는 반면, 상기 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질을 투여한 경우 약 5일(120시간) 까지 약물혈중농도가 검출되는 것을 알 수 있다.As shown in FIG. 6 , in the case of oral administration and subcutaneous injection treatment group (control group), it was confirmed that the drug plasma concentration was very low in about 1 day, whereas donepezil was administered using the microneedle patch prepared in the above Example. In one case, it can be seen that the drug plasma concentration is detected up to about 5 days (120 hours).
다음으로, 랫트에게 상기 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질을 투여하되, 도네페질 농도를 43 mg/kg, 80 mg/kg, 125mg/kg으로 각각 다르게 조절하여 약물혈중농도 양상을 비교하였고, 그 결과를 도 7에 나타내었다.Next, donepezil was administered to the rat using the microneedle patch prepared in the above Example, but the donepezil concentration was adjusted differently to 43 mg/kg, 80 mg/kg, and 125 mg/kg to compare the drug plasma concentration pattern. and the results are shown in FIG. 7 .
도 7에 나타난 바와 같이, 약물혈중농도는, 투여농도에 비례하여 증가하며 약 3일 이상 지속될 수 있음을 알 수 있다.As shown in FIG. 7 , it can be seen that the drug blood concentration increases in proportion to the administered concentration and can last for about 3 days or more.
다음으로, 랫트에게 상기 실시예에서 제조한 마이크로니들 패치를 사용해 도네페질을 투여하되, 도네페질 80 mg/kg을 투여한 후 1시간만에 제거한 경우와 3일간 적용한 경우 약물혈중농도 양상을 비교하였고, 그 결과를 도 8에 나타내었다.Next, donepezil was administered to the rat using the microneedle patch prepared in the above Example, and the drug plasma concentration pattern was compared when removed within 1 hour after administration of donepezil 80 mg/kg and when applied for 3 days. , the results are shown in FIG. 8 .
도 8에 나타난 바와 같이, 1시간만에 마이크로니들을 제거한 경우 36시간만에 약물농도가 빠르게 감소되는 것을 확인할 수 있었으며, 이로부터 약물혈중농도를 특정 수준으로 유지하기 위해서는 마이크로니들 패치를 일정 시간동안 피부에 부착하고 유지해야 함을 알 수 있다.As shown in FIG. 8 , when the microneedle was removed in 1 hour, it was confirmed that the drug concentration was rapidly decreased in 36 hours. You will find that you have to adhere to the skin and hold on to it.
Claims (16)
상기 마이크로니들을 일 면에서 지지하며 약물을 포함하는 약물지지층;
상기 마이크로니들이 지지된 약물지지층 면의 반대측 면에 접하여 구비되며, 약물을 포함하지 않는 지지체; 및
상기 약물지지층이 접하여 있는 지지체 면의 반대측 면에 접하여 구비되는 밀폐성(occlusive) 배면층 필름을 포함하는 마이크로니들 패치이되,
상기 밀폐성 배면층 필름은, 접하고 있는 지지체 면을 덮으며, 피부에 직접 부착 가능하도록 연장 형성된 점착층을 더 포함하는 것을 특징으로 하는, 마이크로니들 패치.
microneedles containing drugs;
a drug support layer supporting the microneedle on one side and containing a drug;
a support that is provided in contact with the surface opposite to the surface of the drug support layer on which the microneedle is supported, and does not contain a drug; and
A microneedle patch comprising an occlusive back layer film provided in contact with the surface opposite to the surface of the support to which the drug support layer is in contact,
The hermetic backing layer film, covering the surface of the support in contact with the microneedle patch, characterized in that it further comprises an adhesive layer extended to be directly attached to the skin.
상기 마이크로니들은 피부 내부로 침투해 용해됨에 따라 약물이 방출되는 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
The microneedle patch, characterized in that the drug is released as the microneedle penetrates into the skin and dissolves.
상기 마이크로니들은 히알루론산(Hyaluronic acid), 폴리비닐피롤리돈(polyvinylpyrrolidone; PVP), 폴리비닐알코올(polyvinyl alcohol; PVA), 소디움 카르복시메틸 셀룰로오스(sodium carboxymethyl cellulose) 및 당류로 이루어지는 군으로부터 선택되는 1종 이상의 혼합물로 형성된 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
The microneedle is 1 selected from the group consisting of hyaluronic acid, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), sodium carboxymethyl cellulose and saccharides. A microneedle patch, characterized in that it is formed of a mixture of more than one species.
상기 당류는 단당류, 이당류 및 다당류로 이루어지는 군으로부터 선택되는 1종 이상인 것을 특징으로 하는, 마이크로니들 패치.
4. The method of claim 3,
The saccharide is a microneedle patch, characterized in that at least one selected from the group consisting of monosaccharides, disaccharides and polysaccharides.
상기 단당류는 과당(Fructose), 갈락토스(Galactose), 글루코스(Glucose) 및 만노스(Mannose)로 이루어지는 군으로부터 선택되는 1종 이상이고;
상기 이당류는 수크로스(Sucrose), 락토스(Lactose), 말토스(maltose), 트레할로스(Trehalose), 투라노스(Turanose) 및 셀로비오스(Cellobiose)로 이루어지는 군으로부터 선택되는 1종 이상이고; 및
상기 다당류는 덱스트란(Dextran), 디에틸아미노에틸-덱스트란(Diethylamino ethyl-Dextran), 덱스트린(Dextrin), 셀룰로오스(Cellulose) 및 베타-글루칸(β-Glucans)으로 이루어지는 군으로부터 선택되는 1종 이상인 것을 특징으로 하는, 마이크로니들 패치.
5. The method of claim 4,
the monosaccharide is at least one selected from the group consisting of fructose, galactose, glucose, and mannose;
The disaccharide is at least one selected from the group consisting of sucrose, lactose, maltose, trehalose, turanose and cellobiose; and
The polysaccharide is at least one selected from the group consisting of dextran, diethylamino ethyl-dextran, dextrin, cellulose, and beta-glucan (β-Glucans). Characterized in that, microneedle patch.
상기 약물을 포함하는 약물지지층은, 피부로부터 증발되는 수분에 의해 겔화 가능한 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
The drug support layer containing the drug, microneedle patch, characterized in that it can be gelled by moisture evaporated from the skin.
상기 약물지지층의 겔화로 인해, 약물지지층에 포함되어 있던 약물이 방출되는 것을 특징으로 하는, 마이크로니들 패치.
7. The method of claim 6,
Due to the gelation of the drug support layer, the microneedle patch, characterized in that the drug contained in the drug support layer is released.
상기 약물지지층의 겔화로 인해 방출되는 약물은, 마이크로니들로 인해 형성된 피부의 미세 기공을 통해 체내로 흡수되는 것을 특징으로 하는, 마이크로니들 패치.
8. The method of claim 7,
The drug released due to the gelation of the drug support layer is a microneedle patch, characterized in that it is absorbed into the body through the micropores of the skin formed by the microneedle.
상기 약물지지층은 히알루론산(Hyaluronic acid), 폴리비닐피롤리돈(polyvinylpyrrolidone; PVP), 폴리비닐알코올(polyvinyl alcohol; PVA), 소디움 카르복시메틸 셀룰로오스(sodium carboxymethyl cellulose), 폴록사머(poloxamer), 카보머(carbomer), 히프로멜로오스(hypromellose), 히드록시프로필셀룰로오스(Hydroxypropyl cellulose; HPC), 히드록시에틸셀룰로오스(Hydroxyethyl cellulose; HEC), 소디움 알지네이트(sodium alginate), 당류, 글리세린(glycerin), 프로필렌글리콜(propylene glycol), 폴리에틸렌글리콜 400(polyethylene glycol 400) 및 소르비톨(sorbitol; SB)로 이루어지는 군으로부터 선택되는 1종 이상의 혼합물로 형성된 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
The drug support layer is hyaluronic acid, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), sodium carboxymethyl cellulose (sodium carboxymethyl cellulose), poloxamer (poloxamer), carbomer (carbomer), hypromellose, hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), sodium alginate, saccharides, glycerin, propylene glycol (propylene glycol), polyethylene glycol 400 (polyethylene glycol 400), and sorbitol (sorbitol; SB), characterized in that formed of a mixture of one or more selected from the group consisting of, microneedle patch.
상기 밀폐성 배면층 필름은 피부로부터 증발되는 수분에 대해 반투과성이거나 방습성인 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
The hermetic backing layer film is semi-permeable to moisture evaporated from the skin or moisture-proof, it characterized in that the microneedle patch.
상기 밀폐성 배면층 필름은 피부로부터 증발되는 수분의 손실을 막아, 상기 약물지지층의 겔화를 촉진하는 것을 특징으로 하는, 마이크로니들 패치.
11. The method of claim 10,
The hermetic back layer film prevents the loss of moisture evaporated from the skin, characterized in that it promotes the gelation of the drug support layer, microneedle patch.
상기 밀폐성 배면층 필름은 피부로부터 증발되는 수분의 손실을 막음으로써, 마이크로니들 패치가 피부에 부착된 동안 마이크로니들로 인해 형성된 피부의 미세 기공이 개방된 상태로 유지되는 것을 특징으로 하는, 마이크로니들 패치.
12. The method of claim 11,
The airtight back layer film prevents the loss of moisture evaporated from the skin, so that the micropores of the skin formed by the microneedles are maintained in an open state while the microneedle patch is attached to the skin. .
상기 피부의 미세 기공이 개방된 상태로 유지되어, 약물지지층의 겔화로 인해 방출되는 약물이 지속적으로 피부로 흡수되는 것을 특징으로 하는, 마이크로니들 패치.
13. The method of claim 12,
Microneedle patch, characterized in that the micropores of the skin are maintained in an open state, and the drug released due to the gelation of the drug support layer is continuously absorbed into the skin.
상기 마이크로니들 패치의 사용 전에, 점착층을 보호하는 보호층을 더 포함하는 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
Before use of the microneedle patch, the microneedle patch, characterized in that it further comprises a protective layer to protect the adhesive layer.
상기 마이크로니들은 원뿔 형상, 사각뿔 형상 및 삼각뿔 형상으로 이루어지는 군으로부터 선택되는 1종 이상의 형상으로 형성되는 것을 특징으로 하는, 마이크로니들 패치.
According to claim 1,
The microneedle patch, characterized in that it is formed in at least one shape selected from the group consisting of a cone shape, a quadrangular pyramid shape and a triangular pyramid shape.
상기 지지체는 생체적합성 고분자류, 세라믹류, 및 금속류로 이루어지는 군으로부터 선택되는 1종 이상으로 형성된 것을 특징으로 하는, 마이크로니들 패치.According to claim 1,
The support is a microneedle patch, characterized in that it is formed of at least one selected from the group consisting of biocompatible polymers, ceramics, and metals.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210021611A KR102610991B1 (en) | 2021-02-18 | 2021-02-18 | Microneedle patch system for transdermal drug delivery |
| PCT/KR2022/001550 WO2022177205A1 (en) | 2021-02-18 | 2022-01-28 | Microneedle patch system for transdermal drug delivery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210021611A KR102610991B1 (en) | 2021-02-18 | 2021-02-18 | Microneedle patch system for transdermal drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220118019A true KR20220118019A (en) | 2022-08-25 |
| KR102610991B1 KR102610991B1 (en) | 2023-12-06 |
Family
ID=82930921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210021611A KR102610991B1 (en) | 2021-02-18 | 2021-02-18 | Microneedle patch system for transdermal drug delivery |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102610991B1 (en) |
| WO (1) | WO2022177205A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101549086B1 (en) * | 2014-11-10 | 2015-09-02 | 주식회사 스몰랩 | Micro-needle and micro-needle patch |
| JP2016189844A (en) | 2015-03-31 | 2016-11-10 | 日本写真印刷株式会社 | Microneedle patch |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003225735A1 (en) * | 2002-03-11 | 2003-09-29 | Altea Therapeutics Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
| EP3024530A4 (en) * | 2013-07-22 | 2017-04-19 | Tuo Jin | Fabrication process of phase-transition microneedle patch |
| KR101724654B1 (en) * | 2014-06-02 | 2017-04-12 | 주식회사 아모라이프사이언스 | Micro-needle patch and menufacturing method thereof |
| KR20160095576A (en) * | 2015-02-03 | 2016-08-11 | 김아영 | Microneedle array using zaungo and patch thereof |
| KR101878414B1 (en) * | 2016-08-12 | 2018-07-13 | 연세대학교 산학협력단 | Micro-needle patch, manufacturing method thereof and diagnosis method using the same |
| KR20190123642A (en) * | 2018-04-24 | 2019-11-01 | 주식회사 엠씨넷 | Multi-layer microneedles having excellent skin permeability, patches comprising the same and a method for preparing the patches |
-
2021
- 2021-02-18 KR KR1020210021611A patent/KR102610991B1/en active IP Right Grant
-
2022
- 2022-01-28 WO PCT/KR2022/001550 patent/WO2022177205A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101549086B1 (en) * | 2014-11-10 | 2015-09-02 | 주식회사 스몰랩 | Micro-needle and micro-needle patch |
| JP2016189844A (en) | 2015-03-31 | 2016-11-10 | 日本写真印刷株式会社 | Microneedle patch |
Non-Patent Citations (1)
| Title |
|---|
| Formation and Closure of Microchannels in Skin Following Microporation, Pharm Res (2011) 28:82-94, doi: 10.1007/s11095-010-0122-x |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102610991B1 (en) | 2023-12-06 |
| WO2022177205A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110917176B (en) | Implantable sustained-release microneedle patch and preparation method thereof | |
| WO2020043167A1 (en) | Quick implantable slow-release microneedle patch and preparation method therefor | |
| CN114146046B (en) | Coated microneedle with multilayer structure, preparation method thereof and microneedle patch comprising coated microneedle | |
| EP2213284A1 (en) | Preparation for application to body surface and preparation holding sheet for application to body surface | |
| JP7090299B2 (en) | Microneedle transdermal patch containing donepezil | |
| CN110799238B (en) | Local anesthesia microneedle array for dentistry | |
| JP2016518868A (en) | Microstructure arrays for delivery of active agents | |
| WO2021244630A1 (en) | Heat-resistant implantable polymer microneedle and preparation method therefor and application thereof | |
| KR102517754B1 (en) | Soluble microneedle patch for tranexamic acid delivery | |
| KR102110571B1 (en) | Manufacturing method of transdermal patch comprising effective ingredients | |
| KR102610991B1 (en) | Microneedle patch system for transdermal drug delivery | |
| CA3083252C (en) | Transdermal therapeutic system on the basis of adhesive plasticizer-polymer matrices | |
| KR20180006116A (en) | Micro bullet integrated transdermal patch containing rivastigmin and preparation method thereof | |
| KR20210036130A (en) | Temperature sensitive polymer composition, polymer gel composite, medical articles and cosmetic articles using the same | |
| KR20210036463A (en) | Temperature sensitive polymer composition, polymer gel composite, medical articles and cosmetic articles using the same | |
| WO2022215693A1 (en) | Microneedle array for local anesthesia for dental use | |
| KR102187439B1 (en) | Minimally invasive skin biopsy method using microneedle patch | |
| KR20240045574A (en) | Temperature sensitive polymer composition, polymer gel composite, medical articles and cosmetic articles using the same | |
| KR20230024668A (en) | Micro-needle patch | |
| KR20190029108A (en) | Microneedle array comprising mixture of DNA fragments | |
| KR20170046043A (en) | Soluble microneedle patch for delivery of anti-leukoplakia drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |